Rob Blackie

Jean Schmitt, who heads Jolt Capital focusing on deep tech investments, and Rob Blackie, founder of Crampton Blackie, discuss the critical state of RNA in Europe. They address the hurdles of commercialization and investment, revealing stark funding disparities with North America. Insights from their landmark report highlight the regulatory challenges faced by biotech startups. They argue for a supportive environment to foster innovation and explore the impact of COVID vaccine advancements. The conversation emphasizes the need for strategic partnerships to unlock RNA's full potential.